Sector: Healthcare · Industry: Biotechnology
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is headquartered in Stockholm, Sweden.
Headquarters: Stockholm · Employees: 6 · Website: https://www.ibtherapeutics.com
Informatica Inc. (INFA) is a publicly traded company in the Healthcare sector (Biotechnology). Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Macroplane tracks Informatica Inc.'s (INFA) supply chain. Tracked supply-chain partners include CGI INC (GIB).
Search companies · Macro trends · Industries · Product categories · Baskets